Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sandro Pignata
Observed names:
S Pignata,
S. Pignata
Institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Observed institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
ORCID:
0000-0002-8836-2633
Observed ORCID:
0000-0002-8836-2633
OpenAlex ID:
A5088974590
Dostarlimab and niraparib in primary advanced ovarian cancer
2025
·
A.-C. Hardy-Bessard
, E. Pujade-Lauraine
, et al.
·
Annals of Oncology
·
43
PDF
Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
2019
·
I.L. Ray-Coquard
, P. Pautier
, et al.
·
Annals of Oncology
·
39
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors
2021
·
M. Bartoletti
, L. Musacchio
, et al.
·
Cancer Treatment Reviews
·
25
176O Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
2022
·
S. Nagao
, P. Harter
, et al.
·
Annals of Oncology
·
8
718MO Mirvetuximab soravtansine (MIRV) in recurrent platinum-sensitive ovarian cancer (PSOC) with high folate receptor-alpha (FRα) expression: Results from the PICCOLO trial
2024
·
A.A. Secord
, B.R. Corr
, et al.
·
Annals of Oncology
·
7
PDF
Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial
2026
·
L. Paracchini
, A. Velle
, et al.
·
ESMO Open
·
6
39MO Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer
2023
·
R. Boidot
, M.G.B. Blum
, et al.
·
ESMO Open
·
5
PDF
Endometrioid borderline ovarian tumour: A multicentre analysis from the MITO-14 study
2025
·
G. Candotti
, A. Bergamini
, et al.
·
European Journal of Surgical Oncology
·
4
Physical Activity, Nutritional Status, and Health-Related Quality of Life in Newly Diagnosed Cancer Patients: Evidence from the NUTRISCREEN Project
2026
·
Giuseppe Porciello
, Anna Crispo
, et al.
·
Nutrients
·
3
PDF
Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial
2025
·
M. Bartoletti
, A. Passarelli
, et al.
·
ESMO Open
·
3
PDF
PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey
2025
·
M. Turinetto
, C. Marchetti
, et al.
·
ESMO Open
·
3
PDF
1119P Lenvatinib plus pembrolizumab (L + P) vs treatment of physician’s choice (TPC) for advanced endometrial cancer (EC): 5-year outcomes from study 309/KEYNOTE-775
2025
·
V. Makker
, N. Colombo
, et al.
·
Annals of Oncology
·
2
Corrigendum to “Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials”
2024
·
L. Arenare
, R. Di Liello
, et al.
·
ESMO Open
·
2
45P MITO39: Effiacy and tolerability of PLD-trabectedin in the treatment of relapsed ovarian cancer after maintenance therapy with PARP-i, a MITO observational case-control study
2023
·
M. Turinetto
, S. Pignata
, et al.
·
ESMO Open
·
1
590P Ki67 as a predictor of response to PARP inhibitors in platinum sensitive BRCA wild type ovarian cancers: MITO 37 retrospective study
2022
·
V. Tuninetti
, E. Ghisoni
, et al.
·
Annals of Oncology
·
1
31P Survival outcomes in BRCA pathogenetic mutated, variant of unknown significance, and wild type ovarian cancer patients treated with PARP inhibitors
2022
·
L. Musacchio
, C. Marchetti
, et al.
·
Annals of Oncology
·
1
PDF
The effect of financial difficulties on clinical outcomes in Italian cancer patients: a pooled analysis of 16 academic prospective clinical trials
2016
·
F. Perrone
, C. Jommi
, et al.
·
Annals of Oncology
·
1
Cancer in migrant populations: evidence from a regional oncology network
2026
·
Elisabetta Coppola
, Chiara D’Alessio
, et al.
·
BMC Public Health
32MO Long-term follow-up shows improved outcomes for stage IC-IV MOGCTs in a multicentre international analysis
2026
·
A. Bergamini
, S. Suyanto
, et al.
·
ESMO rare cancers.
Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: A multicenter analysis from the Campania oncological network
2025
·
E. Perri
, R. Tambaro
, et al.
·
European Urology Open Science
IUC24400-75 Real-world outcomes of second-line pembrolizumab in urothelial cancer: Campania network analysis
2025
·
R Tambaro
, E Perri
, et al.
·
The Oncologist
51P Efficacy of PARP inhibitors in patients with advanced high grade serous ovarian cancer according to BRCA domain mutations
2023
·
R. Buonaiuto
, G. Neola
, et al.
·
ESMO Open
PDF
1346P Diagnosis of early-stage cancers in carriers of BRCA1/2 pathogenetic variants: Two years of activity of the multidisciplinary team for hereditary cancers
2022
·
M. Pensabene
, S. Greggi
, et al.
·
Annals of Oncology
ENGOT-en9/LEAP-001: A phase III, randomized, active-controlled, open-label study of pembrolizumab plus lenvatinib versus paclitaxel plus carboplatin for newly diagnosed advanced or recurrent endometrial cancer
2020
·
C. Marth
, C. Vulsteke
, et al.
·
Gynecologic Oncology
Show more works
View as search
Works count:
25
Citation count:
154
H-index:
6
I10-index:
3
Year
Topic
Type